Search

The growing global population has amplified the demand for food, making the international trade of livestock a significant threat to animal and public health due to the increased risk of zoonotic disease transmission through animal movement or the consumption of their products. Biosecurity measures (BSMs) and vaccination are two essential tools that, when effectively implemented, can significantly reduce the spread of diseases from livestock. However, their failure not only escalates the burden of disease but also compromises food security and public health. Weak or poorly enforced BSMs can undermine the efficacy of vaccinations, creating challenges against disease prevention efforts. Conversely, robust BSMs such as nutritional and environmental management, routine monitoring of disease, farm management, and hygiene provide a critical foundation for successful vaccination programs by minimizing disease exposure and ensuring vaccine effectiveness. Inappropriate vaccination administration, inadequate cold chain management, and the frequency of immunosuppressive illnesses are also reported as contributing factors to vaccine failure. This review delves into the interconnected roles of BSMs and vaccination, unveiling the importance of the implementation of biosecurity principles in preventing vaccine failure. It also explores how the integration of biosecurity practices and vaccination strengthens animal health systems, mitigates zoonotic risks, and enhances overall food safety. Future research should concentrate on integrated biosecurity techniques by strengthening on-farm biosecurity protocols, proper handling and administration of vaccines, careful disease surveillance, and awareness programs thereby increasing the resilience of our livestock industry against notable diseases.

The One Health framework has emerged as a central paradigm for addressing emerging infectious diseases (EIDs) by recognizing the interconnectedness of human, animal, and environmental health. Despite increasing global adoption, the ethical dimensions of One Health remain conceptually fragmented and inconsistently operationalized across research, governance, and policy. This descriptive review synthesizes ethical challenges associated with One Health approaches to EIDs across six interrelated domains: animal ethics and welfare, public health ethics, environmental and planetary ethics, governance and policy, research ethics in outbreak settings, and emerging ethical frameworks. Drawing on peer-reviewed literature, policy documents, and conceptual scholarship, the review identifies four major cross-cutting ethical tensions. First, anthropocentric priorities continue to dominate One Health implementation, subordinating animal welfare and ecological integrity to human-centered outcomes. Second, tensions between collective welfare and individual rights become acute during outbreaks, imposing disproportionate burdens on marginalized populations. Third, persistent distributive, procedural, and epistemic injustices shape global and local responses, especially affecting low- and middle-income countries, indigenous communities, and non-human populations. Fourth, a substantial implementation gap exists between the articulation of ethical principles and their translation into enforceable institutional practice. The review further incorporates emerging ethical challenges related to antimicrobial resistance (AMR) within One Health contexts, empirical evidence from major outbreaks including COVID-19, Ebola, and avian influenza, and perspectives from Global South scholarship to address equity dimensions. Emerging frameworks, including One Health Ethics, Planetary Health Ethics, ethics of care, indigenous relational ethics, and epistemic justice approaches, offer promising foundations for more inclusive governance, yet remain insufficiently integrated into operational decision-making. The review argues that One Health ethics must evolve into a rigorous interdisciplinary field supported by practical governance tools, equitable research frameworks, transparent accountability mechanisms, and inclusive policymaking. Without such developments, the transformative potential of One Health will remain ethically and institutionally constrained. 

This study critically reviews the literature on the prevalence and genotypic distribution of Bovine Leukemia Virus (BLV) in Asia, specifically targeting enzootic bovine leukosis, a chronic disease affecting cattle’s life and milk production along with reduced fat yield, that causing economic losses due to increased susceptibility to pathogens. European countries are eradicating BLV but Asia has a high prevalence, particularly in Asian cattle. Enzootic bovine leukosis (EBL) has distinct clinical stages: asymptomatic, persistent lymphocytosis, and lymphosarcoma. It typically occurs in adult animals, with 60% being asymptomatic during the aleukemic stage, 30% developing persistent lymphocytosis, and 5% developing lymphoma. Databases like PubMed and Google Scholar were used to search molecular and prevalence studies from 2000-2024, focusing on Asian countries. Prevalence of bovine leukosis (BL) in Asia varies significantly, with high rates in central and eastern regions. BLV is a global disease, has increased in Asia with highest prevalence in central Asia about 40.0–84.0% (Kazakhstan), 35% in Eastern Asia (Japan), and 58.3% in Southeast Asia (Thailand). BLV genotypes G1, G4, G6, G7, G12, G3, G4, G6, G7, and G10 are prevalent in various regions of Asia, with G1 being most prevalent globally. These genotypes might be spread due to animal trading, and animal domestication, affecting various countries. This review provides the current status of enzootic bovine leukosis in Asia, emphasising the need for a closed trading system to control the disease.

CRISPR has become a revolutionary tool for cancer biology and therapy with unprecedented precision for genome editing. Besides cancer, CRISPR is also under research for possible use in the treatment of viral diseases, such as Bovine Viral Diarrhea Virus (BVDV), a serious livestock problem. Through enabling gene modifications to be made to individual genes, CRISPR is used in identifying oncogenic drivers, characterizing tumor suppressor networks, and designing innovative therapeutics. This review focuses on the various uses of CRISPR for cancer studies with special attention to methods like gene knockout, gene activation, and base editing that each has a great potential for correcting oncogenic mutations and restoring tumor suppressor activity. Moreover, CRISPR's capacity to regulate viral replication, as that of BVDV, signifies its dual role in oncology as well as in viral pathogenesis. Interventions based on CRISPR such as chimeric antigen receptor (CAR) T cell therapy and synthetic lethality are essentially revolutionizing cancer therapy by improving immune responses and capitalizing on the specificity that is characteristic of cancer cells. However, off-target effects, tumor heterogeneity, and ethical dilemmas remain onerous challenges for clinical application. CRISPR delivery systems, despite playing a central role in advancing cancer therapies, also have prospects in optimizing the effectiveness of treatment against viral pathogens like BVDV. Advances in delivery systems using nanoparticles and viral vectors are mitigating against these challenges and improving efficacy and specificity of CRISPR reagent in vivo. In addition to this, continued progress in new technologies such as prime editing and base editing is predicted to improve precision and efficacy of CRISPR-based therapy. Since CRISPR technology is continuously developing, CRISPR's potential to treat both cancer and viral infections, like BVDV, simultaneously will be instrumental in precision medicine. This review highlights the revolutionary potential of CRISPR to revolutionize cancer treatment paradigms and brings hope for more effective and individualized therapy. With potential developments to emergent and potentiated CRISPR tools and reagents, it is predicted that they will play a center stage role in precision oncology and promote better patient results.

Microorganisms have a crucial role in processing food and preservation, as well as enhancing the nutritional and sensory qualities of food products. Microorganisms are utilized as additives for altering the nature of a substance and have a significant role in fermentation. Molds (e.g., Penicillium roqueforti and Geotrichum candidum), yeasts (e.g., Saccharomyces cerevisiae), and lactic acid bacteria are used to increase the shelf life of foodstuffs and the nutritional quality of processed foods in the fermentation process. Acetic acid bacteria and lactic acid bacteria are used in applied microbiology to increase the flavor of different manufactured foods. Further, bacteria, in the form of probiotics, are involved in the processing of food. Various strains of different bacteria are used as probiotics to increase the quality and preservation of foodstuffs. Bifidobacterium and Lactobacillus are used to produce prebiotics and postbiotics as well. This article discusses the many ways that microorganisms may be added to food and supplements such as probiotics, prebiotics, postbiotics, and symbiotics in order to fulfill the world's food demand and make up for the scarcity of arable land. It also discusses the future prospects and challenges of this field.

Necrotic enteritis is an important disease of poultry that causes economic loss to the broiler industry. Clostridium perfringens is an important bacterium that is responsible for causing necrotic enteritis. Antibiotics are mainly used to control C. perfringens but due to resistance antibiotics are banned in many countries like Canada, Hong Kong, and the European Union. Many alternatives such as probiotics, essential oils, and postbiotics have been developed to control C. perfringens. Among them, probiotics are very important because they can increase beneficial bacteria in the intestine, create a competitive environment in the gut region, and prevent the adhesion and colonization of pathogenic bacteria such as C. perfringens. Probiotics cause immune system modulation, reducing inflammatory markers such as cytokines. Lactobacillus based probiotics also cause weight gain, improve feed conversion ratio, and decrease mortality in poultry which in turn increase profit margin. Several studies have reported that when poultry populations were challenged with C. perfringens then these probiotics prevented intestinal lesions, provided anti-inflammatory effects to the intestine, prevented damage to the villi, and did not allow C. perfringens to form its colony in the intestine. The main aim of this review paper is to explain the updated information on necrotic enteritis, the damages caused to the gut, and the mechanism of actions through which Lactobacilli work against C. perfringens.